Myelodysplastic Syndromes

Latest News

There was significant variability in test frequency and detection rates among patients with AML and MDS. | Image credit: Saiful52-stock.adobe.com

Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

By Rose McNulty

July 11th 2025

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.

A cornerstone of the proposed guidance is the emphasis on robust clinical trial design and appropriate patient selection. | Image Credit: wladimir1804 - stock.adobe.com

FDA Releases Draft Guidance for MDS Drug Development

By Sabrina Serani

July 10th 2025

$Patients with RS-negative low-risk MDS who were relapsed or refractory to or ineligible for ESAs appeared to experience clinical benefit with imetelstat treatment in a post hoc analysis. | Image credit: fotogurmespb - stock.adobe.com$

Imetelstat Shows Benefit in RS-Negative, Lower-Risk MDS

July 1st 2025

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com

Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

By Rose McNulty

June 18th 2025

The findings support the use of luspatercept as the first-line standard of care for anemia treatment in patients with MDS. | Image Credit: wanchalerm - stock.adobe.com

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

By Rose McNulty

June 5th 2025

More News

Expert on MDS

February 7th 2022

Interchangeability Between Oral and IV Agents in HR-MDS

Bruce Feinberg, DO Ryan Haumschild, PharmD, MS, MBA Amer Zeidan, MD Tracey Iraca

Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.

Expert on MDS

January 31st 2022

Oral Therapy for HR-MDS: Addressing Patient Adherence

Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.

Expert on MDS

January 31st 2022

Practical Considerations for the Use of HMAs in Higher-Risk MDS

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.

Experts on MDS

January 31st 2022

Impact of an Oral HMA on the HR-MDS Treatment Landscape

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.

Expert on MDS

January 24th 2022

Higher-Risk MDS: When to Use HMA Therapy or Lenalidomide

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.

Expert on MDS

January 24th 2022

Goals of Therapy for Patients With Myelodysplastic Syndromes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.

Expert on MDS

January 17th 2022

Factors in Selecting Therapy for Myelodysplastic Syndromes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.

Experts on MDS

January 17th 2022

Considering the Role of ESAs and Blood Transfusions in MDS Management

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.

Expert on MDS

January 10th 2022

Gaps in the Diagnosis and Treatment of Myelodysplastic Syndromes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

Experts consider shortcomings in the identification and management of myelodysplastic syndromes.

Expert on MDS

January 10th 2022

Educating Patients and Caregivers on MDS Subtypes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.

Expert on MDS

January 4th 2022

Identifying Myelodysplastic Syndromes Subtypes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

Expert perspectives on the changes in MDS subclassifications as understandings of the disease have evolved.

Expert on MDS

January 3rd 2022

Approaching Patient and Caregiver Education on Myelodysplastic Syndromes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

Shared insight on how to best educate patients and caregivers on the broad nature of myelodysplastic syndromes.

Experts on MDS

December 21st 2021

Understanding the Nature of Myelodysplastic Syndromes

Bruce Feinberg, DO Amer Zeidan, MD Ryan Haumschild, PharmD, MS, MBA Tracey Iraca

A panel of experts discuss the complex nature of myelodysplastic syndromes and concurrent subclassifications.

Researchers Develop Improved Flow Cytometric Score for MDS Diagnosis

January 16th 2021

Researchers Develop Improved Flow Cytometric Score for MDS Diagnosis

A flow cytometric score developed in 2012, which uses 4 parameters to distinguish low-grade myelodysplastic syndromes (MDS) from nonclonal cytopenias, is simple and practical for screening patients with MDS, according to research published in the American Journal of Translational Research.

Analysis Reveals High Cost of Discontinued HMA Treatment for MDS

January 15th 2021

Analysis Reveals High Cost of Discontinued HMA Treatment for MDS

New research underscores the substantial economic burden associated with early discontinuation of guideline-recommended hypomethylating agent (HMA) therapy among patients with refractory anemia with excess blasts, a diagnosis that substantially overlaps with higher-risk myelodysplastic syndrome (MDS).

PROs Used in Low-Risk MDS Found to Have Strong Face, Content Validity

January 9th 2021

PROs Used in Low-Risk MDS Found to Have Strong Face, Content Validity

A recent study evaluated the content validity of patient-reported outcome instruments used in low-risk myelodysplastic syndrome (MDS).

Study Finds IWG 2006 Response Criteria Valid in Patients With Higher-Risk MDS

January 7th 2021

Study Finds IWG 2006 Response Criteria Valid in Patients With Higher-Risk MDS

Complete response to first-line therapy, as determined by the International Working Group 2006 response criteria, can be used as a surrogate end point for overall survival in higher-risk patients with myelodysplastic syndromes (MDS), according to a study published in Cancer Medicine.

Is a New Classification and Prognosis System Possible for Myelodysplastic Syndromes?

January 2nd 2021

Is a New Classification and Prognosis System Possible for Myelodysplastic Syndromes?

Jaime Rosenberg

Integrating novel parameters into conventional risk stratification systems may better define patient subgroups in myelodysplastic syndromes (MDS), thus creating a more enhanced classification and prognostic scoring system for patients, say researchers.

Unanswered Questions Remain in Optimal Management of RBC Transfusions in MDS

January 1st 2021

Unanswered Questions Remain in Optimal Management of RBC Transfusions in MDS

Jaime Rosenberg

Questions remain about the optimal approach to transfusion management in myelodysplastic syndromes (MDS), particularly in the outpatient setting, leading a pair of researchers to review current evidence.

Heterogenous Nature of MDS Warrants Further Research, Review Finds

December 23rd 2020

Heterogenous Nature of MDS Warrants Further Research, Review Finds

Jaime Rosenberg

With a goal of moving toward more individualized therapeutic approaches, researchers said future advancements in understanding myelodysplastic syndrome (MDS) molecular mechanisms are needed to offer clinical decision making guidance.

Bone marrow cell

December 19th 2020

Gene Expression Signatures Linked With Response to HMA Treatment in Patients With MDS

Jaime Rosenberg

Their work may help to further understanding of the molecular mechanisms of hypomethylating agents (HMAs) and offer a guide for determining which patients are likely to respond to such treatment.

Target on leukemia cell

December 18th 2020

For Patients With HMA-Resistant MDS, What Are Their Options?

Jaime Rosenberg

For patients who are resistant to hypomethylating agent (HMA) treatment, there are no formal treatment recommendations, but several options, spanning from novel HMAs to chemotherapy, have been or are currently being studied in the setting.

Enlarged drop of blood

December 12th 2020

Study Finds Significant Survival Advantage for Patients With MDS Who Have HLA-Matched Donor for HCT

Jaime Rosenberg

The abstract, presented at the 2020 American Society of Hematology Annual Meeting and Exposition, found favorable overall survival and leukemia-free survival for these patients.

NCCN Adds Oral Decitabine, Cedazuridine Combo to MDS Guidelines

December 8th 2020

NCCN Adds Oral Decitabine, Cedazuridine Combo to MDS Guidelines

Inqovi is an orally administered, fixed-dose combination of the DNA hypomethylating agent, decitabine, and cedazuridine, an inhibitor of cytidine deaminase.

Dr Abby Statler Speaks on Eligibility Criteria Exclusions for MDS Clinical Trials

February 21st 2020

Dr Abby Statler Speaks on Eligibility Criteria Exclusions for MDS Clinical Trials

Our outcomes suggest that eligibility criteria for patients with MDS relevant to liver function, renal function, and comorbidities may be relaxed, especially for those who have minor renal function abnormalities who have shown to have similar clinical outcomes to those without such abnormalities, said Abby Statler, PhD, MPH, MA, research associate at Cleveland Clinic.

Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS

December 28th 2018

Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS

Laura Joszt, MA

Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.

Early Data Suggests CC-486 Relatively Safe, Effective in Thrombocytopenic Patients With MDS

November 21st 2018

Early Data Suggests CC-486 Relatively Safe, Effective in Thrombocytopenic Patients With MDS

There have been few therapeutic options for treating thrombocytopenia in MDS patients. Now, early phase data suggest that CC-486 (oral azacytidine, an investigational drug sponsored by Celgene) is a relatively safe and effective treatment for thrombocytopenic patients with MDS.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions